Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer

A Walz, A Ugolkov, S Chandra, A Kozikowski… - Clinical Cancer …, 2017 - AACR
Glycogen synthase kinase-3β (GSK-3β), a serine/threonine protein kinase, is a complex
regulator of numerous cellular functions. GSK-3β is a unique kinase which is constitutively …

The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment

G Augello, MR Emma, A Cusimano, A Azzolina… - Cells, 2020 - mdpi.com
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified
because of its key role in the regulation of glycogen synthesis. However, it is now well …

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

I Sahin, A Eturi, A De Souza, S Pamarthy… - Cancer biology & …, 2019 - Taylor & Francis
As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways,
glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer …

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and …

G Shaw, L Cavalcante, FJ Giles, A Taylor - Journal of Hematology & …, 2022 - Springer
Background Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple
roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 …

Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response

L Ding, VS Madamsetty, S Kiers, O Alekhina… - Clinical Cancer …, 2019 - AACR
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common
malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an …

Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity

J Wei, J Wang, J Zhang, J Yang, G Wang… - European journal of …, 2022 - Elsevier
Glycogen synthase kinase-3β (GSK-3β) is a conserved serine/threonine kinase that
participates in the transmission of multiple signaling pathways and plays an important role in …

Glycogen synthase kinase 3β in tumorigenesis and oncotherapy

R He, S Du, T Lei, X Xie, Y Wang - Oncology Reports, 2020 - spandidos-publications.com
Glycogen synthase kinase 3β (GSK 3β), a multifunctional serine and threonine kinase, plays
a critical role in a variety of cellular activities, including signaling transduction, protein and …

[HTML][HTML] Nobiletin suppresses cholangiocarcinoma proliferation via inhibiting GSK3β

L You, J Lin, Z Yu, Y Qian, Y Bi, F Wang… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Background: Cholangiocarcinoma (CCA) is a type of hepatobiliary cancer characterized by
uncontrolled cell proliferation, with a poor prognosis and high mortality. Nobiletin (NBT) is a …

Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors

NA Lozinskaya, DA Babkov, EV Zaryanova… - Bioorganic & medicinal …, 2019 - Elsevier
Glycogen synthase kinase 3β (GSK-3β) is a widely investigated molecular target for
numerous diseases including Alzheimer's disease, cancer, and diabetes mellitus. Inhibition …

Glycogen synthase kinase-3β inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis

A Jeffers, W Qin, S Owens, KB Koenig, S Komatsu… - Scientific Reports, 2019 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median
survival of 3 years after diagnosis. Although the etiology of IPF is unknown, it is …